Publications of Udo Reichl
All genres
Talk (263)
381.
Talk
Next-Generation Virus Production: From Clone, to AMBR, to Perfusion and Very High Virus Yield. International Society for Vaccines (ISV) Annual Congress, Lausanne (Switzerland) (2023)
382.
Talk
Increase in supply through use of new technologies for high yield vaccines. Flanders Vaccine, Brussels (Belgium) (2023)
383.
Talk
Intensified production for a yellow fever - ZIKA virus vaccine candicate. Democratization of biotherapies: new manufacturing modalities and intensification's, Oxford, UK (2023)
384.
Talk
Intensifiying OSB processes for high titer virus production. 5th large scale meeting: Orbital shaken bioreactors, Girona (Spain) (2023)
385.
Talk
Identification of newly synthesized proteins in microbial communities using BONCAT and click chemistry. 5th International Metaproteomics Symposium, Avignon (France) (2023)
386.
Talk
Process development for multi-gram-scale synthesis of nucleotide sugars using in-vitro multi-enzyme cascades. Eurocarb21 (The 21st European Carbohydrate Symposium), Paris (France) (2023)
387.
Talk
Development of an in-vitro multi-enzyme cascade for the synthesis of uridine diphosphate N-acetylgalactosamine using a DoE approach. GlycoBioTec 2023, Berlin, Germany (2023)
388.
Talk
Absolute quantification of influenza A virus proteins during single-round replication in different host cells. 6th Workshop on Virus Dynamics, Nagoya (Japan) (2023)
389.
Talk
Influenza A virus defective interfering particles as antiviral agents. 32nd Annual Meeting of the Society for Virology (GfV), Ulm (Germany) (2023)
390.
Talk
Influenza A virus OP7 defective interfering particles: Cell culture-based production and antiviral efficacy in vivo. Cell Culture Engineering (CCE) XVIII , Cancun (Mexico) (2023)
391.
Talk
In-depth characterization and cell culture-based production of influenza A virus defective interfering particles. ACTIP fellowship session, Dublin (Ireland) (2023)
392.
Talk
Semi-continuous Propagation of Influenza A Virus and Its Defective Interfering Particles: Analyzing the Dynamic Competition To Select Candidates for Antiviral Therapy. Vir-AI-DIP Workshop, Hamburg (Germany) (2023)
393.
Talk
Activated sugar for oligosaccharides synthesis. GlycoBioTec 2023, Berlin, Germany (2023)
394.
Talk
OP7, a defective interfering particle with mutations: in vitro infection experiments, intracellular model, impact of mutations and mode of antiviral action. 6th Workshop on Virus Dynamics, Nagoya (japan) (2023)
395.
Talk
Multiscale model of influenza A virus and defective interfering particle co-infection in animal cell culture. Vir-AI-DIP Workshop, Hamburg (Germany) (2023)
396.
Talk
Synthesis of Synthetic Lipid-Linked Oligosaccharides for In-Vitro Glycoengineering of Hemagglutinin Peptides by a Cell-Free, Multi-Enzyme Cascade. GlycoBioTec 2023, Berlin, Germany (2023)
397.
Talk
Chemoenzymatic glycosylation of polypeptides using eukaryotic oligosaccharyltransferase and synthetic lipid-linked glycans. Glyco26, Taipei (Taiwan) (2023)
398.
Talk
Novel approach towards vaccine manufacturing: from single-cell cloning to high-yielding influenza virus production. 4th Global Bioprocessing, Bioanalytics and ATMP Manufacturing Congress, Dublin (Ireland) (2023)
399.
Talk
A quest for the best influenza producing clonal MDCK cell line: intensifying by design of experiments, ambr15 and bench-top bioreactor cultivations. World Biopharm Forum 2023 - Democratisation of biotherapies: new manufacturing modalities and intensifications, Oxford (United Kingdom) (2023)
400.
Talk
New avenues for biomarker discovery in human blood plasma via an improved in-depth analysis of the low-abundant N-glycoproteome. GlycoBioTec 2023, Berlin, Germany (2023)